Budesonide/carmoterol

Drug Profile

Budesonide/carmoterol

Alternative Names: Carmoterol/budesonide; CHF-5188

Latest Information Update: 31 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Chiesi
  • Class Antiasthmatics; Bronchodilators; Ethanolamines; Glucocorticoids; Pregnenediones; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Asthma

Most Recent Events

  • 17 Feb 2010 Chiesi Farmaceutici initiates enrolment in a Phase-II trial for Asthma in UK
  • 01 Jan 2010 Phase-II clinical trials in Asthma in Germany (Inhalation)
  • 16 Sep 2009 Final efficacy and adverse events data from a phase II trial in Asthma presented at the 19th Annual Congress of the European Respiratory Society (ERS-2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top